Learn more about Replagal
Replagal (agalsidase alfa)® is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease.
This site is designed as a resource to provide information about Replagal.
Patient Information
Patient Information Leaflet (PIL), providing information for patients who have been prescribed Replagal, including: what Replagal is and what it is used for; how it is taken; possible side effects; and further information.
Learn MorePublic Information & Resources
Public information about Replagal and Fabry disease, including the Patient Information Leaflet (PIL),Summary of Product Characteristics (SPC) and other useful websites.
Learn MoreThe information on this website is intended only to provide information about Replagal (agalsidase alfa). This information should not be used in place of advice from your GP or other healthcare professional.
This website is intended for residents of the United Kingdom only. This website has been produced by Shire Human Genetic Therapies, a business within the Shire group of companies. The website has been developed in accordance with industry and legal standards to provide information for the general public, patients and their families, and also healthcare professionals about Replagal. Shire Human Genetic Therapies makes every reasonable effort to include accurate and current information. However, the information provided on the website is not exhaustive. References for published sources of information cited on the Replagal website have been provided on the relevant pages.
Sponsored by Shire Human Genetic Therapies.
UK Offices: Hampshire International Business Park, Chineham, Basingstoke, Hampshire
RG24 8EP
Email: HGTmedcomm@shire.com
